Cricket great and pharmacy leader join to welcome the launch of a new pharmacy-based asthma management product
Former Australian cricket captain Michael Clarke was in Sydney this week to launch a new electronic hand-held device and smartphone app, which are designed to extend care for asthma patients beyond the clinic.
Australian designed and manufactured, Wheezo fills a gap in the market, allowing users to better understand and manage their asthma between doctors’ appointments, according to Marjan Mikel, CEO of eHealth technology developer Respiri.
Together the wheezo device and app record breathing for 30 seconds and identify wheeze. It can help patients monitor and manage their asthma symptoms and triggers.
The app stores the patient’s Asthma Action Plan, medication use and local, real-time weather information such as pollen and pollution levels. Wheezo also allows patients to share their asthma data with their healthcare professional.
Launching the product at North Sydney Oval this week, Mr Clarke said he had little knowledge about asthma and the impact it can have before his daughter was diagnosed at the age of two. With no family history, the diagnosis came as a surprise.
“With no family history of asthma in either side, it was, for me, a freak out moment when she had her first attack,” he said.
“We welcome any solution that can help us manage her asthma and allow her to live a normal life. I want her to go outside and play, jump on the trampoline or swim in the pool so it’s comforting to have the right information close at hand.”
“The advantage of the wheezo device and app is it provides an inexperienced father, who has never suffered asthma, a lot of very powerful information. With the device being so easy to use and the app on your phone, wheezo allows me to monitor my daughter’s asthma whenever, wherever.”
Also speaking at the launch was community pharmacist Krysti-Lee Rigby, who said she is “excited to see the device available in community pharmacy. This device actually helps patients, parents, pharmacists and other health care professionals.”
“For the first time, there is a device which will tell a parent when a child is experiencing a wheeze, while the Wheezo app monitors pollen as well as air pollutants, and logs and tracks symptoms, giving parents the ability to greater manage their child’s condition, as well as providing peace of mind”.
“While its a great device for children, adults can use it as well to monitor their asthma symptoms,” said Ms Rigby, who is a professional services pharmacist at Pharmacy Platform.
“Some patients overuse ventolin or underuse puffers. The Wheezo device and app give them the empowerment and education they need for better management”.
To assist with bringing wheezo to market, Respiri has partnered with pharmaceutical company Cipla to sell and distribute wheezo in pharmacies nationally for $99.50, and an asthma management app subscription from $9.99/month, first month free. It is available from 1 December.